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Chronic inflammation is a major trigger of local and systemic bone loss. Disintegration of 
cell–matrix interaction is a prerequisite for the invasion of inflammatory tissue into bone. 
CD44 is a type I transmembrane glycoprotein that connects a variety of extracellular matrix 
proteins to the cell surface. Tumor necrosis factor (TNF) is a major inducer of chronic 
inflammation and its overexpression leads to chronic inflammatory arthritis. By generating 
CD44
 
 
 
/
 
  
 
human TNF-transgenic (hTNFtg) mice, we show that destruction of joints and 
progressive crippling is far more severe in hTNFtg mice lacking CD44, which also develop 
severe generalized osteopenia. Mutant mice exhibit an increased bone resorption due to 
enhanced number, size, and resorptive capacity of osteoclasts, whereas bone formation and 
osteoblast differentiation are not affected. Responsiveness of CD44-deficient osteoclasts 
toward TNF is enhanced and associated with increased activation of the p38 mitogen-
activated protein kinase. These data identify CD44 as a critical inhibitor of TNF-driven 
joint destruction and inflammatory bone loss.
 
Chronic inflammation in combination with sys-
temic bone loss and severe joint damage is a
characteristic of rheumatoid arthritis (RA; refer-
ences 1–4). Given its destructive course and the
associated functional impairment, RA is a highly
disabling disease (5). Recently, osteoclasts have
been identified as key cell population–mediating,
inflammation-triggered bone erosions (6). In
fact, chronic inflammatory tissue, such as the RA
synovial membrane, provides a suitable microen-
vironment to promote differentiation of osteo-
clasts (7). Once formed, these cells pave the path
for invasion of inflammatory tissue into bone.
Strikingly, osteoclast-deficient mice can develop
arthritis, but inflammation is not accompanied
by bone destruction (8, 9). The factors that regu-
late osteoclast formation and bone destruction in
the course of chronic inflammatory processes,
however, are poorly characterized.
The membrane-bound surface receptor
CD44 provides a link between extracellular ma-
trix components and the cell surface (10). CD44
comprises a family of transmembrane glycopro-
teins encoded by a single gene. Due to great
variability in splicing, 17 different isoforms can
be generated. Interestingly, CD44
 
 
 
/
 
  
 
mice lack-
ing all isoforms of CD44 have no obvious
phenotype (11). Nevertheless, CD44 has been
shown as functionally significant in hematopoie-
sis, lymphocyte homing, and development of
tumor metastasis. Furthermore, a major physio-
logical role of CD44 is the maintenance of tissue
homeostasis through connecting several matrix
components, such as hyaluronic acid, chon-
droitin sulfate, and osteopontin to the cell
surface (10, 12, 13). Therefore, we hypothe-
sized that function of CD44 may gain criti-
cal importance in chronic inflammatory con-
ditions, because resulting tissue damage and
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bone destruction require disintegration of normal cell–matrix
interactions. To address this hypothesis, we crossed CD44
 
 
 
/
 
 
 
mice with human TNF-transgenic (hTNFtg) mice (14), which
develop a chronic inflammatory arthritis followed by joint de-
struction and osteopenia closely resembling human RA. The re-
sulting CD44
 
 
 
/
 
  
 
hTNFtg mice develop a very aggressive form
of arthritis, which is more severe than in hTNFtg animals. This
phenotype is characterized by increased formation of articular
osteoclasts, which are increased in number and size both in vitro
and in vivo. In addition, loss of CD44 enhances systemic bone
loss induced by TNF overexpression. These results suggest that
CD44 functions as an inhibitor of inflammatory bone loss.
 
RESULTS
Generation and phenotypic characterization of CD44
 
 
 
/
 
  
 
hTNFtg mice
 
To investigate the role of cell–extracellular matrix interac-
tion in inflammatory bone destruction, hTNFtg mice were
crossed with CD44
 
 
 
/
 
  
 
mice. The offspring of all four geno-
types (WT, CD44
 
 
 
/
 
 
 
, hTNFtg, and CD44
 
 
 
/
 
  
 
hTNFtg)
were born in Mendelian frequency and were viable and phe-
notypically indistinguishable at birth. As described, CD44
 
 
 
/
 
 
 
mice developed no obvious phenotype during the entire ob-
servation period (up to week 10) and showed no difference
in size and body weight compared with WT mice. In con-
trast, the two genotypes carrying the TNF transgene (hTNFtg
and CD44
 
 
 
/
 
  
 
hTNFtg) developed clinical signs of arthritis at
the age of 4 wk. In addition, they showed a marked and sig-
nificant reduction of 
 
 
 
20% in body weight.
Clinical investigation revealed progressive joint swelling
in both hTNFtg and CD44
 
 
 
/
 
  
 
hTNFtg mice (Fig. 1 A), but
in the latter, disease activity was significantly enhanced and
progressed significantly faster (Fig. 1 B; P 
 
  
 
0.01), whereas
no articular changes were found in WT and CD44
 
 
 
/
 
  
 
mice.
In addition, grip strength of paws deteriorated significantly
faster in CD44
 
 
 
/
 
  
 
hTNFtg mice, suggesting rapid loss of joint
Figure 1. Clinical signs of arthritis. (A) WT (wt) and CD44 /  mice 
(aged 10 wk) showed normal hind paws, hTNFtg mice developed paw 
inflammation, and CD44 /  hTNFtg showed severe inflammation and 
deformities of paws. Histology (TRAP stain; original magnification of 250) 
of the same paws showing inflammation (arrows) and bone destruction 
(arrowheads; purple spots). (B) Clinical course of paw swelling and loss of 
grip strength between 4 and 10 wk of age. 
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function (Fig. 1 B). These changes were the consequence of
severe synovitis with increased numbers of osteoclasts, result-
ing in destruction of the normal joint architecture.
 
Increased joint destruction and enhanced numbers of 
osteoclasts in the absence of CD44
 
Next, we performed a detailed histological analysis of joints
in the front and hind paws. Inflammatory bone erosions
were significantly increased in CD44
 
 
 
/
 
  
 
hTNFtg mice com-
pared with hTNFtg mice. Osteoclasts were abundant at the
interface of inflammatory synovial tissue and bone (Fig. 2 B).
Quantitative analyses revealed significantly larger areas of
erosions and increased numbers of osteoclasts in CD44
 
 
 
/
 
 
 
hTNFtg mice compared with hTNFtg controls (Fig. 2 A),
suggesting increased generation and activity of osteoclasts in
inflammatory tissue of CD44
 
 
 
/
 
  
 
hTNFtg mice. Moreover,
the osteoclasts of CD44
 
 
 
/
 
  
 
hTNFtg mice appeared to be
much larger in size than those of hTNFtg animals. In addi-
tion, cartilage damage was increased in CD44
 
 
 
/
 
  
 
hTNFtg
mice, as denoted by widespread loss of proteoglycans in the
articular cartilage (Fig. 2 C). Immunohistochemical analyses
revealed significant CD44 expression in osteoclast-rich areas
at the interface of inflammatory tissue and bone in hTNFtg
mice, whereas it was completely absent in CD44
 
 
 
/
 
  
 
hTNFtg
mice (Fig. 2 D). Nevertheless, CD44
 
 
 
/
 
  
 
hTNFtg animals
had similar expression patterns of CD44 ligands, such as hy-
aluronic acid (Fig. 2 E) or osteopontin (not depicted).
 
Severe systemic osteopenia in CD44
 
 
 
/
 
  
 
hTNFtg mice is due 
to enhanced bone resorption
 
Next, we investigated whether bone was also affected at sites
distant from inflammatory tissue. Of note, hTNFtg mice re-
semble a model of inflammation-triggered generalized bone
loss (15). Histological analysis of the axial and peripheral skel-
eton revealed similar bone mass and structure in WT and
CD44
 
 
 
/
 
  
 
mice (Fig. 3 A). In contrast, hTNFtg mice exhibited
bone loss in both the axial and peripheral skeletal compartment,
which was significantly aggravated in CD44
 
 
 
/
 
  
 
hTNFtg mice
(Fig. 3 A). Microcomputed tomography (micro-CT) analysis
revealed that low bone mass in CD44
 
 
 
/
 
  
 
hTNFtg mice was
due to a decrease of trabecular structures as well as thinning of
cortical bone (Fig. 3, B and C).
To address the bone phenotype of CD44
 
 
 
/
 
  
 
hTNFtg
mice in more detail, we analyzed bones of all four genotypes
by histomorphometry. Trabecular bone volume was compa-
rable in WT and CD44
 
 
 
/
 
  
 
mice. hTNFtg mice showed a
significantly lower trabecular bone volume, which further
decreased in CD44
 
 
 
/
 
  
 
hTNFtg mice (Fig. 4, A and B).
These differences were based on the low numbers of trabec-
ulae among CD44
 
 
 
/
 
  
 
hTNFtg mice as well as decreased tra-
Figure 2. Histological analysis of arthritis. (A) Quantitative morpho-
metric analysis of bone erosion, numbers, and size of synovial osteoclasts 
and cartilage proteoglycan loss. Data are expressed as mean   SD. Aster-
isks indicate significant (P   0.05) difference between hTNFtg and 
CD44 /  hTNFtg mice. (B) TRAP stain showing osteoclasts (purple, arrows) 
in inflammatory bone erosions of hTNFtg and CD44 /  hTNFtg mice. 
(C) Toluidine blue stain indicating cartilage damage due to loss of pro-
teoglycans (destained areas, arrowheads). (D) Immunohistochemistry 
showing expression of CD44 (brown). (E) Detection of hyaluronic acid 
content in the paws of hTNFtg and CD44 /  hTNFtg mice by hyaluronic 
acid binding protein (brown). Original magnification of 100 (C) and 400 
(B, D, and E). 
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becular thickness. In addition, CD44
 
 
 
/
 
  
 
hTNFtg mice
showed a massive increase in numbers of osteoclasts and os-
teoclast-covered surface not only compared with WT and
CD44
 
 
 
/
 
  
 
mice (Fig. 4, A and B), but also compared with
hTNFtg mice. In contrast, osteoblast numbers and osteo-
blast-covered surface (not depicted) were not different be-
tween hTNFtg mice and CD44
 
 
 
/
 
  
 
hTNFtg mice, suggest-
ing that the low bone volume of CD44
 
 
 
/
 
  
 
hTNFtg mice
might be due to increased bone resorption. These data were
further supported by the finding that serum parameters of
bone resorption (cross-laps) were highest in CD44
 
 
 
/
 
  
 
hTNFtg
mice, whereas serum osteocalcin levels as parameter of bone
formation did not differ between the two hTNFtg genotypes
(Fig. 4 C).
 
Functional characterization of bone cells from CD44
 
 
 
/
 
  
 
hTNFtg mice
 
To characterize the functional changes of bone cells leading
to the highly destructive and osteopenic phenotype of
CD44
 
 
 
/
 
  
 
hTNFtg mice, we analyzed in vitro osteoclasto-
genesis and osteoblastogenesis. Upon stimulation with
M-CSF and receptor activator of NF-
 
 
 
B ligand (RANKL),
comparable amounts of tartrate-resistant acidic phosphatase
(TRAP)
 
  
 
multinucleated osteoclasts were formed in cell
cultures from WT and CD44
 
 
 
/
 
  
 
mice, whereas osteoclasto-
genesis was enhanced in cultures from hTNFtg mice, as de-
scribed previously (16). Remarkably, osteoclastogenesis was
substantially more increased in CD44
 
 
 
/
 
  
 
hTNFtg mice, as
denoted from the formation of numerous, giant-sized os-
teoclasts (Fig. 5 A). In line with this finding, the analysis of
the functional state of osteoclasts by measuring bone re-
sorption pits revealed extensive areas of bone resorption in
CD44
 
 
 
/
 
  
 
hTNFtg mice (Fig. 5 B). Enumeration showed a
higher number of osteoclasts in CD44
 
 
 
/
 
  
 
hTNFtg mice,
and these cells were bigger in size and displayed an enor-
mously increased capacity to form resorption pits (Fig. 5 C).
Time response curves revealed that osteoclasts formed ear-
lier, more abundantly, and persisted for a longer time (Fig.
5 C). These differences were based on a higher prolifera-
tive activity of hTNFtg osteoclasts, independent of CD44,
and a significantly reduced rate of apoptosis in CD44
 
 
 
/
 
 
 
hTNFtg cells (Fig. 5 C). CD44
 
 
 
/
 
  
 
hTNFtg osteoclasts
showed a particularly high expression of TRAP and calci-
tonin receptor compared with hTNFtg osteoclasts, whereas
other markers such as MMP-9 and cathepsin K were
equally expressed (Fig. 5 D). On the other hand, osteoblas-
togenesis, as measured by the formation of cells producing
alkaline phosphatase as well as bone nodule formation, was
not different between hTNFtg and CD44
 
 
 
/
 
  
 
hTNFtg mice
(not depicted).
Figure 3. Histological and micro-CT analysis of systemic bone. 
(A) Von Kossa staining of vertebrae and tibiae from 10-wk-old WT, CD44 / , 
hTNFtg, and CD44 /  hTNFtg mice (original magnification of 25). 
(B) Micro-CT–based 3D reconstruction of vertebrae from hTNFtg and 
CD44 /  hTNFtg mice. (C) Micro-CT showing transversal sections through 
femoral shafts of hTNFtg and CD44 /  hTNFtg mice.JEM VOL. 201, March 21, 2005 907
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Absence of CD44 in bone marrow but not stromal cells is 
critical for the phenotype of CD44 /  hTNFtg mice
To distinguish whether deregulation of inflammatory bone
destruction was due to lack of CD44 on stromal or bone
marrow cells, we generated radiation chimeras of WT,
CD44 / , and hTNFtg genotypes by bone marrow trans-
plantation. hTNFtg mice challenged with hTNFtg bone
marrow served as positive control and exhibited a progressive
destructive arthritis (Fig. 6, A and B). However, when WT
or CD44 /  mice were challenged with hTNFtg bone mar-
row, arthritis did not develop, indicating that overexpression
of TNF by stromal but not bone marrow cells is critical for
induction of arthritis (17). Transfer of WT bone marrow into
hTNFtg mice, on the other hand, led to the development of
a relatively mild arthritis. In contrast, when hTNFtg mice
were challenged with CD44 /  bone marrow, severe arthri-
tis ensued, which was significantly enhanced compared with
arthritis after transfer of WT bone marrow cells to hTNFtg
animals (Fig. 6, A and B). These data suggest that TNF over-
expression by stromal cells together with CD44 deficiency of
bone marrow cells is responsible for the severe inflammatory
and destructive phenotype of CD44 /  hTNFtg mice.
Increased production of IL-1 and IL-6 and enhanced 
activation of p38 mitogen-activated protein kinase (MAPK) 
in osteoclasts of CD44 /  hTNFtg mice
To better define the increase in osteoclastogenesis and bone
destruction in CD44 /  hTNFtg mice, cytokine production,
osteoclastogenic signals, and intracellular signaling pathways of
osteoclasts of the various genotypes were analyzed. Osteoclasts
from CD44 /  hTNFtg mice showed significantly increased
production of IL-1 and IL-6 compared with cells from hTNFtg
mice. Moreover, increased levels of these two cytokines
were observed in the serum of CD44 /  hTNFtg mice (Fig. 7
A). There was no difference between hTNFtg and CD44 / 
hTNFtg mice in the levels of human TNF, murine TNF, and
IL-4. Moreover, the balance of RANKL and its decoy recep-
tor osteoprotegerin (OPG) was equal in hTNFtg and CD44 / 
hTNFtg mice, as shown by almost identically elevated serum
levels of RANKL and OPG in WT and CD44 /  mice (Fig.
7 B). In addition, surface expression of RANKL and M-CSF
receptors, RANK and c-fms, respectively, did not differ
among osteoclast precursors of hTNFtg and CD44 /  hTNFtg
genotypes (Fig. 7 C). Next, we analyzed intracellular pro-
tein kinase activation in hTNFtg and CD44 /  hTNFtg os-
Figure 4. Histomorphometry of systemic bone. (A) Tibial metaphyses 
of WT, CD44 / , hTNFtg, and CD44 /  hTNFtg mice were analyzed for bone 
volume per tissue volume (BV/TV), trabecular number (Tb.N), trabecular 
thickness (Tb.Th), number of osteoclasts per bone perimeter (N.Oc/B.Pm), 
osteoclast surface per bone surface (OcS/BS), and the number of osteo-
blasts per bone perimeter (N.Ob). Data are mean   SD. Asterisks indicate 
significant (P   0.05) differences: *, hTNFtg and CD44 /  hTNFtg com-
pared with WT and CD44 / ; **, CD44 /  hTNFtg compared with hTNFtg. 
(B) TRAP-stained sections of tibial metaphyses from WT, CD44 / , hTNFtg, 
and CD44 /  hTNFtg mice show trabecular bone and osteoclasts (purple, 
arrowheads). Original magnification of 25 (top row) and 200 (bottom row). 
(C) Serum level of deoxypyridinole cross-links (DPD) and osteocalcin in WT, 
CD44 / , hTNFtg, and CD44 /  hTNFtg mice.CD44 AND BONE LOSS | Hayer et al. 908
teoclasts. Phosphorylation of p38 MAPK and to a lesser extent
JNK was markedly increased in CD44 /  hTNFtg compared
with hTNFtg osteoclasts upon stimulation with RANKL
(Fig. 8 A), whereas activation of Akt, Erk, and IkB did not
differ between hTNFtg and CD44 /  hTNFtg osteoclasts.
Remarkably, the addition of RANKL resulted in an enhanced
activation of p38 MAPK in osteoclasts of CD44 /  hTNFtg
mice, which was not observed in hTNFtg mice. The addition
of the p38 MAPK inhibitor SB203580 strongly inhibited os-
teoclastogenesis, emphasizing the central role of p38 MAPK
signaling in osteoclast formation in CD44 /  hTNFtg mice
(Fig. 8 B). This was further supported by immunohistochemi-
cal analyses in vivo, which demonstrated high expression of
p38 MAPK in multinucleated osteoclasts of CD44 /  hTNFtg
mice at sites of erosion fronts, which was more pronounced
than in hTNFtg animals (Fig. 8 C).
Absence of CD44 /  leads to an increase in TNF 
responsiveness by enhanced p38 MAPK activation and a 
decrease of MAPK phosphatase (MKP)-1
In light of the excessive osteoclastogenesis in CD44 /  hTNFtg
but not CD44 /  mice, we hypothesized that TNF may di-
rectly activate CD44 /  osteoclast precursors. This was sup-
ported by the observation that the osteoclastogenic capacity of
RANKL was equal in WT and CD44 /  mice but dramati-
cally different when TNF was present. Even low concentra-
tions of RANKL, which did not induce osteoclastogenesis in
hTNFtg precursors, were sufficient to induce osteoclasts in
CD44 /  hTNFtg precursors (Fig. 9 A). Upon stimulation
with TNF, in vitro osteoclast formation was significantly en-
hanced in cells derived from CD44 /  compared with WT
mice (Fig. 9 A), indicating that the absence of CD44 leads to
an increased TNF responsiveness of osteoclasts. Moreover,
activation of p38 MAPK was more pronounced in cells from
CD44 /  than WT mice upon stimulation with TNF,
whereas it did not differ upon stimulation with RANKL (Fig.
9 B). Interestingly, analysis of p38 MAPK signaling molecules
revealed identical activation of the upstream kinase MKK3/6
but diminished levels of the downstream phosphatase MKP-1
in cells from CD44 /  mice compared with WT mice (Fig. 9
B). Finally, to prove that the absence of CD44 sensitizes for
inflammation-dependent osteoclast formation in vivo, we
challenged WT and CD44 /  mice by subperiosteal injection
of LPS into the calvarial bone. Administration of LPS led to
formation of an inflammatory infiltrate as well as osteoclasto-
genesis. Measurement of osteoclast numbers in the calvarial
Figure 5. Ex vivo analysis of osteoclast formation. (A) Formation of 
TRAP  cells in the presence of M-CSF and RANKL in spleen cells from WT, 
CD44 / , hTNFtg, and CD44 /  hTNFtg mice. (B) Bone resorption assay 
showing formation of resorption pits (arrowheads). Original magnification 
of 100. (C) Quantitative analysis of number, size, and resorptive capacity 
of osteoclasts and time response curve of osteoclastogenesis. Apoptosis 
rate (TUNEL assay) and proliferation rate (MTT assay) of osteoclasts. 
Data are mean   SD. Asterisks indicate significant (P   0.05) difference. 
(D) RT-PCR for osteoclast markers from total RNA of cultivated osteoclasts 
of WT, CD44 / , hTNFtg, and CD44 /  hTNFtg mice.JEM VOL. 201, March 21, 2005 909
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bone showed a significant threefold increase in CD44 / 
mice compared with WT mice (Fig. 9 C).
DISCUSSION
Formation of osteoclasts and consequent joint destruction is a
hallmark of RA. Synovial osteoclast formation is based on the
influx of mononuclear osteoclast precursors into the joint as
well as the articular expression of molecules, such as M-CSF,
RANKL, and TNF, which support osteoclastogenesis (7, 18–
21). Even long-standing and highly active arthritis does not
cause joint destruction if osteoclasts are absent (8, 9). Forma-
tion of osteoclasts, however, is a complex process, which re-
quires fusion of up to 20 single cells and therefore depends on
the disruption of complex cell–matrix interactions.
CD44 is a type I transmembrane glycoprotein that is ex-
pressed on most cell types and interacts with several different
extracellular matrix components, such as hyaluronic acid (10,
22). CD44 plays a major role in the maintenance of tissue
integrity. Interestingly, under physiological conditions defi-
ciency of CD44 results in no major disease phenotype (11).
However, recent studies, which addressed a potential role of
CD44 in models of acute inflammatory reactions in lung and
liver, have shown that deficiency of CD44 leads to a pro-
foundly more aggressive and prolonged course of disease
(23–25.) This was due to altered function of granulocytes,
showing accelerated migration and impaired clearance as
well as impaired lymphocyte apoptosis, respectively. On the
other hand, autoimmune conditions such as collagen-induced
arthritis occur with lower frequency and severity in animals
in which CD44 has been blocked pharmacologically or has
been deleted genetically (26–29). The role of CD44 in
chronic inflammatory disease, which is based on persistent
up-regulation of proinflammatory mediators and is associated
with profound tissue remodeling such as local and systemic
bone loss, is yet unknown.
Until now, a direct role of CD44 in osteoclasts has only
been addressed by in vitro studies. Thus, engagement of
CD44 with matrix ligands or antibodies mimicking matrix
ligands suppressed osteoclast formation (27, 28). This mech-
anism, however, does not appear to be critical in physiologi-
cal conditions, because CD44    mice showed no signs of
increased bone resorption in vitro or in vivo. However, un-
der conditions of chronic inflammation, CD44 emerged as a
critical determinant of osteoclastogenesis. TNF triggered a
far more potent osteoclastogenic response if osteoclast pre-
cursors were CD44 deficient. This was manifested by an ex-
cess of osteoclast formation and generation of giant osteo-
clasts, which enabled rapid bone resorption and accelerated
joint destruction and osteopenia. The mechanism appeared
to depend on a higher sensitivity of CD44-deficient osteo-
clast precursors toward TNF and indicates that osteoclasto-
genesis is deregulated in vitro and in vivo when matrix mol-
ecules fail to interact with monocytes via CD44. This
increased sensitivity resulted from an enhanced signaling
through the p38 MAPK pathway, an essential step during
osteoclastogenesis (30–32), and lead to increased production
of TNF-dependent cytokines, such as IL-1 and IL-6. Both
of them are important for osteoclastogenesis and their induc-
tion by TNF depends on activation of p38 MAPK (33–36).
The increased sensitivity of CD44    mice for TNF-medi-
ated bone loss is further corroborated by the observation that
LPS, which activates the proinflammatory cytokine cascade,
induced enhanced osteoclastogenesis when injected subperi-
osteally into CD44    mice.
CD44 appears to influence molecules upstream of p38
MAPK. MKP-1 is known as an important negative regulator
of p38 MAPK (37). In fact, deficiency in CD44 appears to
down-regulate the downstream phosphatase MKP-1 rather
than increase the activity of the upstream kinases MKK3 and
MKK6. This suggests that extracellular matrix interaction
via CD44 may prevent excessive osteoclast differentiation
through its regulatory role on the p38 MAPK pathway.
Whether increased p38 MAPK signaling also affects the func-
tion of mature osteoclasts is less clear. Increased activation of
p38 MAPK has been found in osteoclasts of CD44 /  hTNFtg
mice in vivo. Moreover, the fact that osteoclast size was
increased in CD44 /  hTNFtg mice in vitro and in vivo and
Figure 6. Development of arthritis in radiation chimeric mice. 
(A) Clinical assessment of arthritis by measurement of paw swelling and grip 
strength. (B) TRAP-stained histological sections showing inflammation and 
bone destruction in the tarsal region from the hind paws 6 wk after bone 
marrow transplantation. b.m., bone marrow. Original magnification of 250.CD44 AND BONE LOSS | Hayer et al. 910
that the rate of apoptosis was low in CD44 /  hTNFtg os-
teoclasts supports this argument. In fact, the life span of osteo-
clasts and their susceptibility to apoptotic cell death is known
as a critical parameter for the size of osteoclasts (36). Thus,
excessive p38 MAPK activity induced by TNF may also in-
crease the survival of osteoclasts in the absence of CD44.
These data also suggest that the interaction of osteopontin
with CD44 is not critical for osteoclastogenesis. Osteopontin
is a phosphorylated glycoprotein, which is expressed at sites
of inflammation and binds to a variety of cell surface recep-
tors, preferentially integrins and CD44 (13). The role of os-
teopontin in autoimmune conditions is rather conflicting.
Mitigation of experimental autoimmune encephalomyelitis
and collagen-induced arthritis have been reported in the ab-
sence of osteopontin, although the latter finding is controver-
sial and has not been observed by others (38–41). Moreover,
the serum transfer model of arthritis is not altered by the ab-
sence of osteopontin (39). From these data, it is evident,
however, that the interaction of osteopontin with CD44 is
not a relevant factor for arthritic bone erosion. It is unclear
whether its interaction with other receptors such as  v 3 in-
tegrin is important, despite the fact that osteopontin expres-
sion in synovial tissue and osteopontin serum levels were not
altered by the absence of CD44 (not depicted).
Figure 7. Cytokine production, bone markers, and surface receptor 
expression. (A) Cytokine levels of hTNF, murine TNF (mTNF), IL-1, IL-4, and 
IL-6 in sera (left) and supernatants (right) from osteoclast cultures isolated 
from WT, CD44 / , hTNFtg, and CD44 /  hTNFtg mice. (B) Serum levels of 
RANKL and OPG in the aforementioned genotypes. (C) FACS analysis of 
surface expression of RANK (by RANKL-FITC) and c-fms (by quantum red-
labeled anti–c-fms antibody) on osteoclast precursors from hTNFtg and 
CD44 /  hTNFtg mice.JEM VOL. 201, March 21, 2005 911
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Absence of CD44 on monocytes and overexpression of
TNF by stromal cells was found to be essential for the ob-
served dramatic deregulation of osteoclast-mediated bone
resorption in CD44-deficient hTNFtg mice, whereas ab-
sence of CD44 on stromal cells and overexpression of
TNF on bone marrow cells did not cause any bone phe-
notype nor arthritis. This indicates that in this disease
model two mechanisms are essentially involved in inflam-
matory bone destruction: (a) Neighboring stromal cells
need to provide excess amounts of proinflammatory fac-
tors, such as TNF, which induce osteoclast differentiation
from mononuclear precursors; and (b) Osteoclastogenesis
must overcome CD44-mediated cell–matrix interactions,
which prevent tissue remodeling and damage. In fact, this
Figure 8. Activation of intracellular signaling pathways. (A) Analysis 
of intracellular protein kinase activation in osteoclasts from hTNFtg and 
CD44 /  hTNFtg mice upon stimulation with RANKL and M-CSF. (B) Inhi-
bition of osteoclastogenesis by p38 MAPK inhibitor SB 203580 evaluated 
by TRAP staining. (C) Immunohistochemical analysis of p38 MAPK and ERK 
phosphorylation in synovial osteoclasts of hTNFtg and CD44 /  hTNFtg 
mice in vivo (brown, arrows). Original magnification of 400.CD44 AND BONE LOSS | Hayer et al. 912
latter regulatory mechanism appears to be highly impor-
tant during chronic overexpression of proinflammatory
cytokines as implied by the severity of bone loss found in
CD44 /  hTNFtg mice. This is additionally supported by
observations that TNF stimulates the interaction of hyalu-
ronic acid with CD44, indicating that TNF itself induces
regulatory cell–matrix interaction. Strengthening of cell–
matrix interactions through CD44 may thus provide a
novel therapeutic principle to counteract tissue damage
due to inflammation.
Figure 9. Osteoclastogenic effects of TNF in the absence of CD44. 
(A) Dose response analysis of RANKL on osteoclast differentiation in WT, 
CD44 / , hTNFtg, and CD44 /  hTNFtg mice (left). Effect of exogenous TNF 
on the formation of osteoclasts in WT and CD44 /  mice (right). (B) Analy-
sis of MAPK activation upon stimulation with RANKL, TNF, or both in 
osteoclasts from WT and CD44 /  mice (left). Assessment of upstream ki-
nase activation and protein phosphatases after stimulation with TNF in 
osteoclasts from WT and CD44 /  mice. (C) Analysis of osteoclast formation 
by TRAP staining (purple, arrows) upon subperiosteal injection of LPS (or PBS) 
in the calvariae of WT and CD44 /  mice. Original magnification of 50.JEM VOL. 201, March 21, 2005 913
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MATERIALS AND METHODS
Animals. Tg197 human TNF transgenic mice (hTNFtg; genetic back-
ground C57BL6; reference 14) and CD44 /  mice (genetic background:
C57BL6; reference 11) were crossed, and F2 generations were identified by
PCR from tail DNA using the following primers: hTNF transgene
construct: 5 -TACCCCCTCCTTCAGACACC-3  and 5 -GCCCTTC-
ATAATATCCCCCA-3 ; CD44 WT: 5 -GGCGACTAGATCCCTCC-
GTT-3  and 5 -ACCCAGAGGCATACCAGCTG-3 ; and CD44 knock-
out: 5 -GTTTCATCCAGCACGCCAT-3  and 5 -ATTCAGGCTGCG-
CAACTGT-3 . All data were generated from littermates. Animals were
killed by cervical dislocation 10 wk after birth. All animal procedures were
approved by the local ethical committee.
Clinical assessment. Paw swelling was assessed in all four paws by using a
semiquantitative score as described previously (8): 0, no swelling; 1, mild
swelling of toes and ankle; 2, moderate swelling of toes and ankle; 3, severe
swelling of toes and ankle. Grip strength (8) was similarly assessed: 0, normal
grip strength;  1, mildly reduced grip strength;  2, severely reduced grip
strength;  3 no grip at all. Assessments were performed in blinded fashion
between weeks 4 and 10 of age.
Histological analyses. 2- m decalcified paraffin-embedded sections were
stained with hematoxylin and eosin, toluidine blue, and TRAP (Leukocyte
Phosphatase Staining Kit; Sigma Diagnostics). For immunohistochemical anal-
yses, sections were incubated with anti-CD44 rat polyclonal antibody (IM-7
clone; BD Biosciences), anti–phospho-p38 MAPK, anti–phospho-ERK, anti–
phospho-JNK monoclonal antibodies (all from Santa Cruz Biotechnology,
Inc.), or biotinylated hyaluronic acid binding protein (Seikagaku).
Micro-CT analysis and histomorphometry. Micro-CT was performed
on vertebrae and long bones using MICRO-CT20 equipment (SCANCO-
Medical). For histomorphometry, tibiae were embedded in methacrylate (Ech-
novit; Heraeus Kulzer) and 3–4- m sections were stained with von Kossa and
toluidine blue. Histomorphometry of metaphyses was performed using an Ax-
ioskop 2 microscope (Carl Zeiss MicroImaging, Inc.) and OsteoMeasure Anal-
ysis System (OsteoMetrics) according to international standards (15, 42).
Ex vivo osteoclastogenesis and bone resorption assay. CD11b 
mononuclear cells ( 90% purity) were isolated from the spleen and cul-
tured in 10% FCS/DMEM supplemented with 30 ng/ml M-CSF and 50
ng/ml RANKL (both from R&D Systems). Inhibition of osteoclastogenesis
was performed in the presence of 0, 2, 10, and 50  M of p38 MAPK inhib-
itor SB 203580 (Calbiochem). Osteoclasts were detected by the presence of
TRAP enzyme activity. Bone resorption assay was performed on 0.4-mm
thick bovine bone slices. Areas of bone resorption were planimetrically ana-
lyzed using the Axioskop 2 microscope (Carl Zeiss MicroImaging, Inc.) and
the OsteoMeasure Analysis System (OsteoMetrics).
RT-PCR. Total RNA was isolated from cultivated osteoclasts using the
RNeasy Mini kit (QIAGEN). 1  g total RNA was used for first strand
cDNA synthesis (Amersham Biosciences) and 1  l cDNA was then used for
PCR using the following primers: cathepsin K: 5 -GGAAGAAGACTCAC-
CAGAAGC-3  and 5 -GTCATATAGCCGCCTCCACAG-3 ; MMP-9:
5 -CCTGTGTGTTCCCGTTCATCT-3  and 5 -CGCTGGAATGATC-
TAAGCCCA-3 ; TRAP: 5 -ACAGCCCCCACTCCCACCCT-3  and
5 -TCAGGGTCTGGGTCTCCTTGG-3 ; calcitonin receptor: 5 -CAT-
TCCTGTACTTGGTTGGC-3  and 5 -AGCAATCGACAAGGAGT-
GAC-3 ; and  -actin: 5 -TGTGATGGTGGGAATGGGTCAG-3  and 5 -
TTTGATGTCACGCACGATTTCC-3 .
Analysis of protein kinase activation. CD11b  mononuclear cells
( 90% purity) were isolated from the spleen and cultured in 10% FCS/
DMEM supplemented with 30 ng/ml M-CSF and 50 ng/ml RANKL (both
from R&D Systems). Cultured osteoclasts were starved in serum-free
DMEM for 2 h on day 3 and stimulated with 50 ng/ml RANKL or 30 ng/
ml M-CSF or 10 ng/ml TNF (Strathmann Biotec AG) or DMEM alone for
5, 10, 30, or only 15 min. Cells were lysed in buffer containing 10 mM Tris,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.2% sodium deoxycholate, 1% NP-
40, 1 mM NaF, 2 mM Na3VO4, and protease inhibitors. Western blotting
was performed with polyclonal antibodies against the phosphorylated forms
of the protein kinases Akt, p38 MAPK, ERK (p44/42 MAP kinase), SAPK/
JNK, IkB and MKK3/MKK6 (all antibodies from Cell Signaling), and for
MKP-1 and MKP-2 (both from Santa Cruz Biotechnology, Inc.). For the
purposes of control, total Akt, p38 MAPK, ERK, SAPK/JNK, IkB (all from
Cell Signaling), and actin (Sigma-Aldrich) were also stained.
Apoptosis and proliferation assay. The apoptosis rate of cultured os-
teoclasts was measured by TUNEL assay using an In Situ Cell Death Detec-
tion Kit (Roche). The proliferation rate of osteoclasts was examined using
an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromid)
assay (Cell Proliferation Kit I; Roche).
FACS analysis. Isolated splenocytes and bone marrow cells from tibiae
and femurs were cultured in DMEM with 30 ng/ml M-CSF for 1–2 d.
Cells were then stained with RANKL-FITC and biotinylated antibody
against c-fms (both provided by J. Penninger, IMBA, Vienna, Austria) using
standard FACS procedures.
Generation of radiation chimeras. 4-wk-old female recipient mice re-
ceived a whole body irradiation of 10 Gy and were then challenged with
5   106 bone marrow cells into the tail vein. Bone marrow cells were iso-
lated from long bones of age- and sex-matched donor mice and washed in
M199 medium (Sigma-Aldrich) supplemented with 10 mM Hepes buffer
(ICN Biomedicals), 10 ng/ml DNase, and 4 ng/ml gentamycin (both from
Sigma-Aldrich). Mice were weekly assessed for clinical signs of arthritis and
killed 6 wk after bone marrow transplantation.
Measurement of cytokines and serum parameters of bone metabo-
lism. Levels of hTNF, murine TNF (mTNF), IL-1 (mIL-1), mIL-4, mIL-6,
soluble RANKL, and OPG in mouse sera and/or in supernatants of osteo-
clast cultures were performed by ELISA according to the manufacturer’s
recommendations (all from R&D Systems). Desoxypyridinolin cross-links
were measured by enzyme immunoassay (Quidel) after previous hydrolysis
of serum samples according to the manufacturer’s recommendations. Osteo-
calcin was measured by immunoradiometric assay (Immutopics).
Subperiosteal injection of LPS. WT (n   5) and CD44 /  mice (n   5)
were anesthetized and received 100  l subperiosteal injection of 500  g LPS
(Sigma-Aldrich) or PBS. Animals were killed 5 d later and calvariae were
fixed in 4.5% formaldehyde for 5 h and were then decalcified in 14% EDTA
(pH adjusted to 7.2 by the addition of 25% ammonia solution; Merck) at 4 C
for 5 d. Osteoclast numbers were analyzed after TRAP staining of paraffin-
embedded sections.
Statistical analysis. Data are given as mean   SEM. Group mean values
were compared by using the unpaired two-tailed Student’s t test.
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